Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001178913-22-000921
Filing Date
2022-03-03
Accepted
2022-03-03 15:34:21
Documents
46
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K zk2227387.htm   iXBRL 10-K 753116
2 DESCRIPTION OF SECURITIES exhibit_4-2.htm EX-4.2 12359
3 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER exhibit_31-1.htm EX-31.1 9735
4 CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER exhibit_32-1.htm EX-32.1 4389
  Complete submission text file 0001178913-22-000921.txt   2838993

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE atms-20211231.xsd EX-101.SCH 26090
6 XBRL CALCULATION FILE atms-20211231_cal.xml EX-101.CAL 16841
7 XBRL DEFINITION FILE atms-20211231_def.xml EX-101.DEF 63235
8 XBRL LABEL FILE atms-20211231_lab.xml EX-101.LAB 212469
9 XBRL PRESENTATION FILE atms-20211231_pre.xml EX-101.PRE 131658
40 EXTRACTED XBRL INSTANCE DOCUMENT zk2227387_htm.xml XML 338507
Mailing Address 18 EAST 16TH STREET NEW YORK NY 10003
Business Address 18 EAST 16TH STREET NEW YORK NY 10003 646-233-1454
Artemis Therapeutics, Inc. (Filer) CIK: 0001062128 (see all company filings)

EIN.: 841417774 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-24431 | Film No.: 22708371
SIC: 2890 Miscellaneous Chemical Products